Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 Combined With Toripalimab and Chemotherapy in Advanced Lung Cancer
NCT05664971Phase 2Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Oct 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tifcemalimab in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Feb 2023; status: completed.
02
Drugs
tifcemalimab
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05664971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664971.